immunoglobulin heavy constant gamma 3 (G3m marker)Genealiases: []
Q-omics provides the consensus-scored IGHG3 profile across patient tissues and cancer cell-line models. IGHG3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHG3 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, IGHG3 RNA expression shows 16,352 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where IGHG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHG3 survival associations across molecular data types. IGHG3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHG3 RNA expression–survival associations across cancer types. High IGHG3 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, SKCM, CESC, UCS and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHG3 RNA expression.
This table summarizes IGHG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IGHG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHG3 shows higher tumor expression in LUAD, HNSC, COAD, KIRC, BLCA and BRCA. The LUAD box plot shows higher IGHG3 RNA expression in tumor versus normal tissue (log2 FC = +2.729, t-test p < 0.001).
This table shows molecular features associated with IGHG3 in patient tissues and cancer cell lines. In patient samples, IGHG3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IGHG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
